Micell raises $62m for MiStent SES
BY
Micell Technologies said last week that it raised a debt-and-equity round worth nearly $62 million from a syndicate of 51 unnamed investors.
Paris-based Micell makes the MiStent SES sirolimus-eluting absorbable polymer coronary stent, designed to treat coronary artery disease. The company, which reported a nearly $26 million round last November, said in a regulatory filing that the funding involved debt, equity and preferred return notes.
In May, at the EuroPCR annual meeting of the annual meeting of the European Assn. of Percutaneous Cardiovascular Interventions, Micell said the MiStent SES met the primary endpoint in the Dessolve III clinical trial…
Read story here at Drug Delivery Business News
